The Latest Cardiac and Vascular News
WALTHAM, Mass.–(BUSINESS WIRE)–Affinia Therapeutics (“Affinia”), an innovative clinical-stage gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially for devastating cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for AFTX-201 for the treatment of BAG3-associated dilated cardiomyopathy (DCM). A potential best-in-class investigational genetic m
Powered by retrospective real-world data from Dandelion Health, the American Heart Association’s AI Impact Report provides a third-party evaluation of Ultromics’ EchoGo® Heart Failure The independent assessment shows EchoGo® Heart Failure could have identified HFpEF 263 days earlier than…
SEATTLE & YOKNEAM, Israel–(BUSINESS WIRE)– #DRIVEWIRE–Rapid Medical FDA-cleared DRIVEWIRE 35, first steerable 0.035-inch guidewire for stroke, neurovascular and peripheral access, after 5,000 DW24 cases.
BOTHELL, Wash.–(BUSINESS WIRE)–FUJIFILM Sonosite, Inc., a global leader in point-of-care ultrasound (POCUS) solutions, today announced the launch of Sonosite iLOOK, a compact ultrasound solution designed specifically for vascular access. Sonosite iLOOK combines a purpose-built user interface, wireless transducer technology, and flexible mounting options in a streamlined solution intended to support vascular access procedures at the bedside Developed specifically for vascular access workflows,
ST. LOUIS, July 21, 2026 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 second quarter on Tuesday, August 11, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. ET that day to discuss the Company’s results and corporate developments.
Proceeds will be used to advance the company’s AI-native cardiovascular platform and expand partnerships with health plans and cardiology practices nationwide ALBUQUERQUE, N.M., July 21, 2026 /PRNewswire/ — Karoo Health, a cardiovascular technology company building an operating system…
NATURE trial, a prospective randomized controlled trial comparing the safety and effectiveness of thrombectomy using enVast before conventional PCI versus standard of care alone, was selected for the prestigious Late-Breaking Clinical Trials session at the European Society of Cardiology…
Route 92 Medical celebrates the 200th patent for its neurovascular intervention portfolio.
MIAMI–(BUSINESS WIRE)–Precision IO Group, the parent company of NeuWave Medical and Quantum Surgical, will present at the Society of Robotic Surgery (SRS) Annual Meeting in Hollywood, Florida, July 22–26, 2026, on booth #325. At the meeting, interventional radiology leaders Prof. Dr. Sean Tutton, MD, Professor of Radiology and Orthopedics, and Dr. Govindarajan Narayanan, MD, FSIR, Professor of Radiology and Chief of Interventional Oncology and the first physician to treat a patient with Epion
PRINCETON, N.J., July 20, 2026 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2026 financial results and recent business…
